Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Regeneron Pharmaceuticals Inc., 3 years.
Regeneron Pharmaceuticals Inc.
Director
The Sherwin-Williams Company
Director
Prudential Financial Inc.
Director
Neurocrine Biosciences Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2025 | The Sherwin-Williams Company | Grant or award | +517 | — | — |
| Jan 3, 2025 | The Sherwin-Williams Company | Grant or award | +25 | $335.00 | $8,439 |
| Jan 2, 2025 | Regeneron Pharmaceuticals Inc. | Grant or award | +166 | — | — |
| Dec 20, 2024 | Regeneron Pharmaceuticals Inc. | Inheritance | +14 | — | — |
| Oct 4, 2024 | The Sherwin-Williams Company | Grant or award | +23 | $372.47 | $8,436 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +10,838 | $413.33 | $4,479,671 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,012 | $1,155.72 | $1,169,589 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −2,368 | $1,156.30 | $2,738,118 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,560 | $1,157.33 | $1,805,435 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −212 | $1,158.02 | $245,500 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −5,352 | $1,159.56 | $6,205,965 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −234 | $1,160.45 | $271,545 |
| Aug 15, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −100 | $1,161.32 | $116,132 |
| Jul 5, 2024 | The Sherwin-Williams Company | Grant or award | +29 | $295.50 | $8,437 |
| May 9, 2024 | Prudential Financial Inc. | Option exercise | +1,935 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.